Determining the Predictive Impact of Donor Parity on the Outcomes of Human Leukocyte Antigen Matched Hematopoietic Stem Cell Transplants: A Retrospective, Single-Center Study Publisher



Azari M^{1, 2} ; Barkhordar M^{1, 2} ; Bahri T^{1, 2} ; Rad S^{2, 3} ; Kamranzadeh Fumani H^{2, 4} ; Mousavi SA^{1, 2} ; Tavakoli Shiraji S^{2, 4} ; Azari M^{1, 2} ; Shafaroudi P^{1, 2} ; Vaezi M^{2, 3} Show Affiliations
Source: Frontiers in Oncology Published:2024

Abstract

Introduction: Donor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor. Methods: We evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen. Results: A total of 1103 allo-HSCT recipients were included. 188 (17.04%) had transplants from parous female donors, whereas 621 (56.30%) and 294 (26.70%) received transplants from male and nulliparous female donors, respectively. HSCTs from parous female donors compared to male and nulliparous females were associated with a significantly higher incidence of grade III-IV acute (a) GVHD (55.27% vs. 11.34 and 10.84%) and extensive chronic (c) GVHD (64.32% vs. 15.52 and 13.65%), as well as lower relapse incidence (RI). Discussion: This study finds that while parous female donors are associated with higher incidences of grade III-IV aGVHD and extensive cGVHD post-allo-HSCT, the advantages, such as a lower RI, outweigh the risks. The results of our study provide valuable insights for donor selection. Copyright © 2024 Azari, Barkhordar, Bahri, Rad, Kamranzadeh Fumani, Mousavi, Tavakoli Shiraji, Azari, Shafaroudi and Vaezi.